HELICOVAXOR® brought together a consortium of three lead European SMEs; Sigmoid Pharma, Telormedix and Gotovax, with research institutions and service providers to develop of an oral Helicobacter pylori vaccine.
The EC FP7 funded portion of the HELICOVAXOR® consortium is now complete and the final report has been submitted. A number of the members of the consortium continue to work together to further research oral adjuvanted vaccines.
The critical needs for successful oral vaccine product development are to
1) find a broadly protective vaccine antigen
2) find or develop a useful, safe, yet effective, mucosal adjuvant
3) develop a useful formulation for oral use that would allow the vaccine-adjuvant mixture to be
a) combined in a single co-ad...
Read More »
Throughout the course of the HELICOVAXOR® project, members of the consortium have continued to raise awareness of the potential for an oral, adjuvanted Helicobacter pylori vaccine through presentations and publications at international conferences and in scientific journals. A list of publications is provided below:
Holmgren J, Svennerholm AM. ”Vaccines against mucosal infections”. Curr Opin Immunol. 2013 Jun;24(3):343-53.
Sjökvist Ottsjö L, Flach CF, Clements J, Holmgren J, Raghavan S. ”A double mu...
Read More »